<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://archotol.ama-assn.org">
<title>Archives of Otolaryngology current issue</title>
<link>http://archotol.ama-assn.org</link>
<description>Archives of Otolaryngology - Head &amp; Neck Surgery provides timely information for physicians and scientists concerned with diseases of the head and neck.  Published monthly, it includes peer-reviewed clinical and basic research from an array of disciplines. Archives is the official publication for the American Academy of Facial Plastic and Reconstructive Surgery, Inc., the American Head and Neck Society, and the American Society of Pediatric Otolaryngology.</description>
<prism:coverDisplayDate>Nov  1 2009 12:00:00:000AM</prism:coverDisplayDate>
<prism:publicationName>Archives of Otolaryngology - Head and Neck Surgery</prism:publicationName>
<prism:issn>0886-4470</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1069?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1070?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1074?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1077?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1082?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1087?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1092?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1098?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1103?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1108?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1112?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1119?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1126?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1132?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1133?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1136?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1137?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1147?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1154?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1158?rss=1" />
  <rdf:li rdf:resource="http://archotol.ama-assn.org/cgi/content/short/135/11/1165?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://archotol.ama-assn.org/icons/misc/titlereprint.gif" />
</channel>

<image rdf:about="http://archotol.ama-assn.org/icons/misc/titlereprint.gif">
<title>Archives of Otolaryngology - Head and Neck Surgery</title>
<url>http://archotol.ama-assn.org/icons/misc/titlereprint.gif</url>
<link>http://archotol.ama-assn.org</link>
</image>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1069?rss=1">
<title><![CDATA[Fall foliage [About the Cover]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1069?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:30 PST</dc:date>
<dc:subject><![CDATA[Otolaryngology/ Head & Neck Surgery, Otolaryngology/ Head & Neck Surgery, Other, Humanities]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.157</dc:identifier>
<dc:title><![CDATA[Fall foliage [About the Cover]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1069</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1069</prism:startingPage>
<prism:section>About the Cover</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1070?rss=1">
<title><![CDATA[About This Journal [About This Journal]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1070?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:title><![CDATA[About This Journal [About This Journal]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1070</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1070</prism:startingPage>
<prism:section>About This Journal</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1074?rss=1">
<title><![CDATA[2009 American Head and Neck Society Presidential Address: Going Global, Reaching Out [Presidential Address]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1074?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Koch, W. M.]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:subject><![CDATA[Otolaryngology/ Head & Neck Surgery, Otolaryngology/ Head & Neck Surgery, Other, Patient-Physician Relationship/ Care, Patient-Physician Relationship, Other, Public Health, World Health]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.176</dc:identifier>
<dc:title><![CDATA[2009 American Head and Neck Society Presidential Address: Going Global, Reaching Out [Presidential Address]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1076</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1074</prism:startingPage>
<prism:section>Presidential Address</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1077?rss=1">
<title><![CDATA[The Legacy and Obligations of the Head and Neck Surgeon: The 2009 Hayes Martin Lecture [Original Article]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1077?rss=1</link>
<description><![CDATA[
<p>I am delighted and extraordinarily honored to be asked to give the Hayes Martin Lecture to what is now the American Head and Neck Society. This lecture represents the crown jewel of the Society of Head and Neck Surgeons, a society that was composed primarily of general and plastic surgeons who focused on head and neck trauma and malignancies. The list of past Hayes Martin lecturers represents the greats of this specialty&mdash;names that for me had extraordinary impact and yet to those generationally behind me are, in all likelihood, unfamiliar: Oliver Bears, Charles Harrold, Harvey Baker, Richard Jesse, Milton Edgerton. Each led their society with a strong hand and attempted to keep the American Society for Head and Neck Surgery (composed predominantly of head and neck&ndash;focused otolaryngologists) at bay. A generation of conflict and contempt gradually seeped away to measured regard from both societies eventuating in a fraternal consolidation of the 2 into what is now the American Head and Neck Society. On May 13, 1998, the American Head and Neck Society evolved from a merger of the American Society for Head and Neck Surgery and the Society of Head and Neck Surgeons. The discipline has benefited measurably.</p>
]]></description>
<dc:creator><![CDATA[Cummings, C. W.]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:subject><![CDATA[Medical Practice, Medical Education, Oncology, Head & Neck Cancer, Otolaryngology/ Head & Neck Surgery, Neoplasms of Head & Neck, Otolaryngology/ Head & Neck Surgery, Other, Public Health, World Health, Surgery, Surgical Interventions, Surgical Oncology, Surgical Interventions, Other, Surgery, Other]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.165</dc:identifier>
<dc:title><![CDATA[The Legacy and Obligations of the Head and Neck Surgeon: The 2009 Hayes Martin Lecture [Original Article]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1081</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1077</prism:startingPage>
<prism:section>Original Article</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1082?rss=1">
<title><![CDATA[Better Than Buffett?: A Report on the Success of the American Head and Neck Society Research Grant Program [Original Article]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1082?rss=1</link>
<description><![CDATA[
<p>It has been well established that a crisis exists in the biomedical research enterprise of clinical surgery departments: the extinction of the surgeon-scientist. A number of factors, including dwindling research funding, decreasing reimbursement from insurance providers, shrinking salaries for researchers, waning interest in academia among graduating residents, and financial pressures on departments for greater clinical productivity, have contributed to this phenomenon in recent years.<sup><cross-ref type="bib" refid="ref-ooa90000-1">1</cross-ref></sup> More importantly, the growing number of basic scientists who are competing with clinicians for investigator-initiated funding from the National Institutes of Health (NIH), along with the competitive advantage of clinicians from internal medicine specialties for these funds, has led to fewer awards to surgeons for research funds.<sup><cross-ref type="bib" refid="ref-ooa90000-2">2</cross-ref></sup> The downturn in the United States economy in 2008 has made these issues more pronounced, threatening the viability of many academic medical centers and the research enterprise in many surgical departments.</p>
]]></description>
<dc:creator><![CDATA[Kupferman, M. E., Moskovic, D. J., Weber, R. S., Boyle, J.]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:subject><![CDATA[Otolaryngology/ Head & Neck Surgery, Otolaryngology/ Head & Neck Surgery, Other, Statistics and Research Methods]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.162</dc:identifier>
<dc:title><![CDATA[Better Than Buffett?: A Report on the Success of the American Head and Neck Society Research Grant Program [Original Article]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1086</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1082</prism:startingPage>
<prism:section>Original Article</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1087?rss=1">
<title><![CDATA[Prophylactic Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma [Original Article]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1087?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To assess the disease-free survival results of prophylactic central neck dissection for papillary thyroid carcinoma preoperatively staged as N0.</p>
<p><b>Design&nbsp;</b> Inception cohort.</p>
<p><b>Setting&nbsp;</b> Head and neck surgery unit at a national oncologic center.</p>
<p><b>Patients&nbsp;</b> Patients with a histologically confirmed diagnosis of stage N0 papillary thyroid cancer but no previous oncologic treatment, no recurrent tumor, and no distant metastasis.</p>
<p><b>Intervention&nbsp;</b> Central neck dissection intended as curative treatment.</p>
<p><b>Main Outcome Measure&nbsp;</b> Disease-free survival. Demographic, clinical, therapeutic, pathologic, and neck recurrence information was also collected.</p>
<p><b>Results&nbsp;</b> A total of 266 patients were included. Mean (SD) follow-up time was 6.9 (4.3) years. Ninety percent of patients had a follow-up longer than 2 years. Prophylactic central neck dissection was performed in 136 patients (51.3%). Of those patients who underwent central neck dissection, 112 had metastatic lymph nodes (82.3%). Neck recurrence occurred in 45 patients (16.9%). Overall, 5-year neck disease&ndash;free survival was 86.8%; it was 88.2% in the central neck dissection group vs 85.6% in the group that did not undergo central neck dissection (<I>P</I>&nbsp;=&nbsp;.72). In the multivariate analysis, factors related to central neck dissection were macroscopic extrathyroidal extension (odds ratio [OR], 2.12; 95% confidence interval [CI], 1.19-3.79) and multifocality (OR, 3.96; 95% CI, 2.08-7.53). In Cox multivariate analysis for disease-free survival, central neck dissection did not show any significant effect.</p>
<p><b>Conclusion&nbsp;</b> Prophylactic central neck dissection did not show any advantage in the rate of neck recurrence in patients with N0 clinical stage disease.</p>
]]></description>
<dc:creator><![CDATA[Zuniga, S., Sanabria, A.]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:subject><![CDATA[Oncology, Head & Neck Cancer, Otolaryngology/ Head & Neck Surgery, Endocrine Disease of Head & Neck, Neoplasms of Head & Neck, Surgery, Surgical Interventions, Surgical Oncology, Endocrine Diseases, Thyroid/ Parathyroid Diseases]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.163</dc:identifier>
<dc:title><![CDATA[Prophylactic Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma [Original Article]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1091</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1087</prism:startingPage>
<prism:section>Original Article</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1092?rss=1">
<title><![CDATA[Central Neck Dissection for Papillary Thyroid Cancer [Original Article]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1092?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To examine the role of central neck dissection (CND) in patients with papillary thyroid cancer (PTC).</p>
<p><b>Design&nbsp;</b> Retrospective analysis of patients treated for PTC between 1993 and 2008.</p>
<p><b>Setting&nbsp;</b> Academic institution.</p>
<p><b>Patients&nbsp;</b> All patients diagnosed with PTC who underwent surgical therapy at our institution.</p>
<p><b>Main Outcome Measures&nbsp;</b> Recurrence, hypocalcemia, hypoparathyroidism, and recurrent laryngeal nerve (RLN) injury.</p>
<p><b>Results&nbsp;</b> A total of 136 patients were treated for PTC, 26 of whom were excluded because their initial resection was performed at another institution. Of the 110 patients who underwent initial surgical therapy, CND was performed in 22 patients (20%), 18 with and 4 without enlarged nodes at the time of surgery. A mean (SD) of 11 (4) lymph nodes were removed, and lymph node metastases were identified in 17 patients (77%). One patient developed a recurrence in the lateral neck at 15 months' follow-up. Eighty-eight patients had no abnormal lymph nodes and did not undergo CND, 2 of whom developed a recurrence (2%) (<I>P</I>&nbsp;=&nbsp;.49) in the central neck at 14 months' and 11 years' follow-up. Permanent RLN injury occurred in no patient who underwent CND and in 1 patient without a CND (1%). Transient hypocalcemia occurred in 19 patients who underwent CND (86%) compared with 54 patients without a CND (61%) (<I>P</I>&nbsp;=&nbsp;.01). Permanent hypoparathyroidism occurred in 1 patient who underwent a CND (5%).</p>
<p><b>Conclusion&nbsp;</b> After total thyroidectomy and CND, recurrence in the central neck is uncommon, but hypocalcemia is more common, raising questions about the use of routine CND in patients with PTC.</p>
]]></description>
<dc:creator><![CDATA[Rosenbaum, M. A., McHenry, C. R.]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:subject><![CDATA[Oncology, Head & Neck Cancer, Otolaryngology/ Head & Neck Surgery, Endocrine Disease of Head & Neck, Neoplasms of Head & Neck, Surgery, Surgical Interventions, Endocrine Surgery, Surgical Oncology, Endocrine Diseases, Thyroid/ Parathyroid Diseases]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.158</dc:identifier>
<dc:title><![CDATA[Central Neck Dissection for Papillary Thyroid Cancer [Original Article]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1097</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1092</prism:startingPage>
<prism:section>Original Article</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1098?rss=1">
<title><![CDATA[Recurrent Laryngeal Nerve: A Plexus Rather Than a Nerve? [Original Article]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1098?rss=1</link>
<description><![CDATA[
<p><b>Objectives&nbsp;</b> To analyze the frequency of extralaryngeal branching (ELB) of the recurrent laryngeal nerve (RLN) in a consecutive series of patients undergoing thyroidectomy by the same group of surgeons during an extended period and to compare our findings with the data available in the literature.</p>
<p><b>Design&nbsp;</b> Retrospective medical record study.</p>
<p><b>Setting&nbsp;</b> Academic research.</p>
<p><b>Patients&nbsp;</b> From March 1, 1983, to September 30, 2008, 2677 patients underwent thyroidectomy. Of these, 1638 patients had surgical information about at least 1 RLN. A total of 1081 patients underwent bilateral operations. During the last 5 years of the study, intraoperative laryngeal nerve monitoring was performed in selected patients using a commercially available system.</p>
<p><b>Main Outcome Measures&nbsp;</b> Information was obtained regarding 2154 RLNs.</p>
<p><b>Results&nbsp;</b> A total of 1390 RLNs (64.53%) had ELB. Among 447 patients in whom intraoperative laryngeal nerve monitoring was used, the anterior branches usually exhibited more electrophysiologic activity.</p>
<p><b>Conclusions&nbsp;</b> Extralaryngeal branching was found in 64.53% of RLNs in this case series. In recent patients with intraoperative laryngeal nerve monitoring, electrophysiologic activity was observed in the branches, particularly the anteriorly situated ones. Recognition of this frequent anatomical configuration and meticulous preservation of all branches are of paramount importance to decrease postoperative morbidity associated with thyroidectomy.</p>
]]></description>
<dc:creator><![CDATA[Cernea, C. R., Hojaij, F. C., De Carlucci, D., Gotoda, R., Plopper, C., Vanderlei, F., Brandao, L. G.]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:subject><![CDATA[Otolaryngology/ Head & Neck Surgery, Endocrine Disease of Head & Neck, Laryngology/ Speech/ Language Pathology, Surgery, Surgical Interventions, Endocrine Surgery, Endocrine Diseases, Thyroid/ Parathyroid Diseases]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.151</dc:identifier>
<dc:title><![CDATA[Recurrent Laryngeal Nerve: A Plexus Rather Than a Nerve? [Original Article]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1102</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1098</prism:startingPage>
<prism:section>Original Article</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1103?rss=1">
<title><![CDATA[Relation of Final Intraoperative Parathyroid Hormone Level and Outcome Following Parathyroidectomy [Original Article]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1103?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To determine if final intraoperative parathyroid hormone (IOPTH) level predicts those at risk for recurrence after parathyroidectomy. Minimally invasive parathyroid exploration guided by preoperative imaging and IOPTH level is an accepted alternative to bilateral exploration for the treatment of primary hyperparathyroidism (HPT). However, additional enlarged, hypercellular parathyroid glands are present in some patients in whom IOPTH levels fall to normal after excision of a single adenoma. At least 15% of patients are normocalcemic with elevated PTH levels (PPTH) after parathyroidectomy. In these patients, a higher risk of recurrent HPT has been found.</p>
<p><b>Design&nbsp;</b> Retrospective review of medical records.</p>
<p><b>Setting&nbsp;</b> University teaching hospital.</p>
<p><b>Patients&nbsp;</b> The records of all 194 patients who underwent successful initial parathyroidectomy for nonfamilial HPT in 2007 and 2008 by 1 surgeon were reviewed.</p>
<p><b>Main Outcome Measures&nbsp;</b> Intraoperative PTH level was measured prior to incision (baseline); at excision of the abnormal gland; at 5, 10, 15, and 20 minutes after excision; and at various additional times as needed. Of the patients, 71% underwent minimally invasive parathyroid exploration. Calcium, PTH, and 25-hydroxyvitamin D levels were measured during the first month after surgery in all patients and after 3 months or more in 80%. Patients were divided into 5 groups depending on the following final IOPTH levels: lower than 10 pg/mL (group l) (to convert PTH to nanograms per liter, multiply by 1.0); 10 to 19 pg/mL (group 2); 20 to 29 pg/mL (group 3); 30 to 39 pg/mL (group 4); and 40 pg/mL or higher (group 5).</p>
<p><b>Results&nbsp;</b> Of the patients, 82% had a single adenoma, 9% had double adenomas, and 9% had 3 or more abnormal glands. The final IOPTH/baseline IOPTH value in groups 1 to 5 was 7%, 11%, 16%, 23%, and 26%, respectively. There was no significant difference in the preoperative calcium among the groups. All 3 patients with persistent HPT and 5 patients with PPTH were in group 5. One of the 96 patients in groups 1 and 2 and 5 of the 72 patients in groups 3 and 4 had PPTH at the last evaluation.</p>
<p><b>Conclusion&nbsp;</b> Patients with a final IOPTH level of 40 pg/mL or higher are at higher risk of having persistent HPT and should be followed up closely and indefinitely following parathyroidectomy.</p>
]]></description>
<dc:creator><![CDATA[Heller, K. S., Blumberg, S. N.]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:subject><![CDATA[Oncology, Head & Neck Cancer, Otolaryngology/ Head & Neck Surgery, Endocrine Disease of Head & Neck, Laryngology/ Speech/ Language Pathology, Neoplasms of Head & Neck, Surgery, Surgical Interventions, Endocrine Surgery, Prognosis/ Outcomes, Endocrine Diseases, Thyroid/ Parathyroid Diseases]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.155</dc:identifier>
<dc:title><![CDATA[Relation of Final Intraoperative Parathyroid Hormone Level and Outcome Following Parathyroidectomy [Original Article]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1107</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1103</prism:startingPage>
<prism:section>Original Article</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1108?rss=1">
<title><![CDATA[Minimally Invasive Parathyroidectomy: Use of Intraoperative Parathyroid Hormone Assays After 2 Preoperative Localization Studies [Original Article]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1108?rss=1</link>
<description><![CDATA[
<p><b>Objectives&nbsp;</b> To review minimally invasive parathyroidectomy (MIP) in patients undergoing initial surgical management of primary hyperparathyroidism (HPT) with preoperative, localizing sestamibi scanning (MIBI), and concordant ultrasonography (US) to determine if intraoperative parathyroid hormone (iPTH) is necessary in these cases. Minimally invasive parathyroidectomy has become an acceptable therapeutic option in treating primary HPT. Preoperative MIBI scanning, high-resolution US with color Doppler flow, and iPTH monitoring have refined this technique.</p>
<p><b>Design&nbsp;</b> Retrospective review.</p>
<p><b>Patients&nbsp;</b> The medical records of 738 consecutive patients who had undergone surgery for HPT. After excluding revision surgical procedures, secondary and tertiary HPT, unavailable intraoperative parathyroid (PTH) data, concomitant thyroid disease requiring thyroidectomy, and patients without preoperative MIBI or US, 428 patients (58%) were included in the study.</p>
<p><b>Results&nbsp;</b> The mean decrease in PTH level was 85%. Of the 428 patients with primary HPT included in the study, 209 patients (49%) had localizing, concordant preoperative MIBI and US. A decline of more than 50% in iPTH levels was observed in 202 patients (97%) after removal of parathyroid tissue localized by MIBI and US. The procedures for 4 patients were converted to bilateral neck explorations after the postexcision PTH level failed to drop less than 50%.</p>
<p><b>Conclusions&nbsp;</b> Our results show that iPTH monitoring may be eliminated in MIP surgery in a carefully selected group of patients who have preoperative, localizing MIBI with concordant US. This potentially allows an increase in operating room efficiency and a decrease in costs while performing MIP.</p>
]]></description>
<dc:creator><![CDATA[Smith, N., Magnuson, J. S., Vidrine, D. M., Kulbersh, B., Peters, G. E.]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:subject><![CDATA[Otolaryngology/ Head & Neck Surgery, Radiology of Head & Neck, Radiologic Imaging, Surgery, Surgical Interventions, Endocrine Surgery, Endoscopy/ Minimally Invasive Surgery, Radionuclide Imaging, Ultrasonography, Endocrine Diseases, Thyroid/ Parathyroid Diseases]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.160</dc:identifier>
<dc:title><![CDATA[Minimally Invasive Parathyroidectomy: Use of Intraoperative Parathyroid Hormone Assays After 2 Preoperative Localization Studies [Original Article]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1111</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1108</prism:startingPage>
<prism:section>Original Article</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1112?rss=1">
<title><![CDATA[N2 Disease in Patients With Head and Neck Squamous Cell Cancer Treated With Chemoradiotherapy: Is There a Role for Posttreatment Neck Dissection? [Original Article]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1112?rss=1</link>
<description><![CDATA[
<p><b>Objectives&nbsp;</b> To determine whether nodal necrosis and node size of 3 cm or larger are risk factors for recurrent neck disease and whether negative computed tomography&ndash;positron emission tomography (CT-PET) results 8 weeks or more after therapy indicate complete response in the neck in patients with N2 disease.</p>
<p><b>Design&nbsp;</b> Retrospective study.</p>
<p><b>Setting&nbsp;</b> State university hospital.</p>
<p><b>Patients&nbsp;</b> Fifty-six patients with head and neck squamous cell cancer and N2 disease treated with chemoradiotherapy were evaluated for persistent or recurrent neck disease. Tumor characteristics analyzed were primary site, T category, nodal size (&lt;3 cm or &ge;3 cm), nodal necrosis based on hypodensity of one-third or more of the node, and type of N2 disease (N2a, N2b, or N2c). Forty-eight of the 56 patients underwent CT-PET to determine treatment response after chemoradiotherapy. Clinical examination, imaging, and pathologic specimens were used to confirm disease recurrence.</p>
<p><b>Main Outcome Measures&nbsp;</b> The number of recurrence events, disease-free interval, and positive posttreatment CT-PET result in the neck.</p>
<p><b>Results&nbsp;</b> Most patients had oropharyngeal tumors (n&nbsp;=&nbsp;37; 66%), T2 tumors (n&nbsp;=&nbsp;21; 38%), nodes 3 cm or larger (n&nbsp;=&nbsp;43; 77%), positive necrosis (n&nbsp;=&nbsp;40; 71%), and N2c disease (n&nbsp;=&nbsp;28; 50%). Multivariate analysis determined that no factors were significant predictors of recurrence, except for positive posttreatment PET results (<I>P</I>&nbsp;&lt;&nbsp;.001). Comparison of CT-PET with nodal recurrence demonstrated a sensitivity of 82%, a specificity of 97%, a negative predictive value of 95%, and a positive predictive value of 90%.</p>
<p><b>Conclusion&nbsp;</b> Posttreatment neck dissections may not be indicated for patients with N2 disease and a negative CT-PET result, even in patients with nodal necrosis and nodes 3 cm or larger.</p>
]]></description>
<dc:creator><![CDATA[Cho, A. H., Shah, S., Ampil, F., Bhartur, S., Nathan, C.-A. O.]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:subject><![CDATA[Oncology, Head & Neck Cancer, Otolaryngology/ Head & Neck Surgery, Neoplasms of Head & Neck, Radiology of Head & Neck, Radiation Therapy, Radiologic Imaging, Surgery, Surgical Interventions, Surgical Oncology, PET/ SPECT Imaging, Drug Therapy, Drug Therapy, Other]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.148</dc:identifier>
<dc:title><![CDATA[N2 Disease in Patients With Head and Neck Squamous Cell Cancer Treated With Chemoradiotherapy: Is There a Role for Posttreatment Neck Dissection? [Original Article]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1118</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1112</prism:startingPage>
<prism:section>Original Article</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1119?rss=1">
<title><![CDATA[Early Prediction of Response to Chemoradiotherapy for Head and Neck Cancer: Reliability of Restaging With Combined Positron Emission Tomography and Computed Tomography [Original Article]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1119?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To assess the role of combined positron emission tomography and computed tomography (PET-CT) in predicting early treatment response at the primary site and in the neck after chemoradiotherapy (CRT) for advanced squamous cell carcinoma of the head and neck (SCCHN).</p>
<p><b>Design&nbsp;</b> Retrospective analysis with a median follow-up of 24 months.</p>
<p><b>Setting&nbsp;</b> Academic, tertiary referral center.</p>
<p><b>Patients and Interventions&nbsp;</b> Thirty-one patients who were treated with concomitant intra-arterial CRT underwent PET-CT 6 to 8 weeks after the completion of treatment. Patients with findings on the physical examination, CT, or PET-CT indicative of persistent disease underwent appropriate surgical intervention for pathological assessment. Patients with a complete clinical response were observed with routine follow-up physical examination for disease recurrence. No evidence of disease at least 6 months after the completion of PET-CT was considered confirmation of complete clinical response.</p>
<p><b>Main Outcome Measures&nbsp;</b> Presence or absence of residual or recurrent disease during the follow-up period was used to calculate the sensitivity, specificity, and positive and negative predictive values of PET-CT for the primary site and the neck.</p>
<p><b>Results&nbsp;</b> Assessment of tumor response at the primary site with PET-CT had a sensitivity, specificity, and positive and negative predictive values of 83%, 54%, 31%, and 92%, respectively. In patients with pretreatment N1 to N3 disease, the sensitivity, specificity, and positive and negative predictive values of posttreatment PET-CT were 75%, more than 94%, more than 75%, and 94%, respectively, and the specificity and negative predictive value for patients with pretreatment N0 disease in the neck were 92% and more than 92%, respectively.</p>
<p><b>Conclusions&nbsp;</b> Negative PET-CT findings accurately determine early disease response at the primary site and in the neck. False-positive findings are common at the primary site. Patients with a negative PET-CT finding after the completion of intra-arterial CRT do not require surgical intervention.</p>
]]></description>
<dc:creator><![CDATA[Malone, J. P., Gerberi, M. A. T., Vasireddy, S., Hughes, L. F., Rao, K., Shevlin, B., Kuhn, M., Collette, D., Tennenhouse, J., Robbins, K. T.]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:subject><![CDATA[Oncology, Head & Neck Cancer, Otolaryngology/ Head & Neck Surgery, Neoplasms of Head & Neck, Radiology of Head & Neck, Radiation Therapy, Radiologic Imaging, Prognosis/ Outcomes, PET/ SPECT Imaging, Drug Therapy, Drug Therapy, Other]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.152</dc:identifier>
<dc:title><![CDATA[Early Prediction of Response to Chemoradiotherapy for Head and Neck Cancer: Reliability of Restaging With Combined Positron Emission Tomography and Computed Tomography [Original Article]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1125</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1119</prism:startingPage>
<prism:section>Original Article</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1126?rss=1">
<title><![CDATA[Predicting Residual Neck Disease in Patients With Oropharyngeal Squamous Cell Carcinoma Treated With Radiation Therapy: Utility of p16 Status [Original Article]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1126?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To identify factors that predict complete response of cervical nodal disease to radiation therapy (RT) in patients with oropharyngeal squamous cell carcinoma (OP-SCCA).</p>
<p><b>Design&nbsp;</b> Histologic analysis of prospectively collected specimens and retrospective medical chart review.</p>
<p><b>Setting&nbsp;</b> Tertiary referral center.</p>
<p><b>Subjects&nbsp;</b> Sixty-nine patients with OP-SCCA treated from January 1, 2002, through June 1, 2008.</p>
<p><b>Intervention&nbsp;</b> Definitive RT, with or without chemotherapy and with or without neck dissection (ND).</p>
<p><b>Main Outcome Measure&nbsp;</b> Presence of a viable tumor in post-RT ND specimen.</p>
<p><b>Results&nbsp;</b> Tissue specimens from 69 patients with OP-SCCA treated primarily with RT, with or without chemotherapy, were evaluated. Of these, 47 (68.1%) were strongly and diffusely positive for p16 expression by immunohistochemical analysis, signifying human papillomavirus positivity. Patients with p16-positive and p16-negative tumors (hereinafter, p16+ and p16&ndash;, respectively) had similarly sized primary tumors on presentation, but p16+ primary tumors were associated with more advanced neck disease (nodal stages N2c-N3; 31.9% vs 4.5% for p16&ndash; tumors) and more contralateral nodes (27.7% vs 4.5% for p16&ndash; tumors). Forty-seven patients (59.0%) underwent planned posttreatment ND (a total of 55 NDs). The NDs performed for p16&ndash; tumors were significantly more likely to have viable tumor in the specimen (50.0% vs 18.0% for p16+ tumors; <I>P&nbsp;</I>&nbsp;=&nbsp;.02). In addition, p16+ necks with residual viable cancer were characterized by incomplete response on post-RT imaging, tobacco and alcohol use, and extracapsular spread on pretreatment imaging.</p>
<p><b>Conclusions&nbsp;</b> In conjunction with other clinical parameters, p16 status can help predict the need for post-RT ND in patients with OP-SCCA. Although close observation may be warranted in selected patients with p16+ tumors, patients with p16&ndash; tumors are at much higher risk for residual neck disease, even when initial nodal disease is less advanced.</p>
]]></description>
<dc:creator><![CDATA[Shonka, D. C., Shoushtari, A. N., Thomas, C. Y., Moskaluk, C., Read, P. W., Reibel, J. F., Levine, P. A., Jameson, M. J.]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:subject><![CDATA[Oncology, Head & Neck Cancer, Otolaryngology/ Head & Neck Surgery, Neoplasms of Head & Neck, Radiation Therapy, Papillomavirus, Human, Prognosis/ Outcomes]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.153</dc:identifier>
<dc:title><![CDATA[Predicting Residual Neck Disease in Patients With Oropharyngeal Squamous Cell Carcinoma Treated With Radiation Therapy: Utility of p16 Status [Original Article]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1132</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1126</prism:startingPage>
<prism:section>Original Article</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1132?rss=1">
<title><![CDATA[Error in Figure in: Oropharyngoplasty With Template-Based Reconstruction of Oropharynx Defects [Correction]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1132?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:subject><![CDATA[Oncology, Head & Neck Cancer, Otolaryngology/ Head & Neck Surgery, Cancer Reconstruction of Head & Neck, Dysphagia, Laryngology/ Speech/ Language Pathology, Neoplasms of Head & Neck, Prognosis/ Outcomes]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.169</dc:identifier>
<dc:title><![CDATA[Error in Figure in: Oropharyngoplasty With Template-Based Reconstruction of Oropharynx Defects [Correction]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1132</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1132</prism:startingPage>
<prism:section>Correction</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1133?rss=1">
<title><![CDATA[Neck Response to Chemoradiotherapy: Complete Radiographic Response Correlates With Pathologic Complete Response in Locoregionally Advanced Head and Neck Cancer [Original Article]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1133?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> The role of neck dissection following chemoradiotherapy (CRT) for locoregionally advanced head and neck cancer is an area of active debate. Patients who have a complete radiographic response may not need dissection, and the extent of neck dissection necessary for those patients with residual disease is unclear.</p>
<p><b>Design&nbsp;</b> Retrospective review of data from a prospectively collected database of patients with locoregionally advanced head and neck cancer treated as part of a phase 2 study of induction chemotherapy followed by concurrent CRT. The results of post-CRT neck computed tomography (CT) imaging and pathologic analysis of the neck dissection specimens were compared to evaluate correlation between radiographic and pathologic response.</p>
<p><b>Results&nbsp;</b> Forty-nine patients underwent 61 hemineck dissections. Overall, 209 neck levels were dissected. Radiologic complete response in the neck was achieved in 39 patients, all of whom had pathologic specimens negative for tumor cells. Ten patients (20%) had a total of 14 neck levels with residual disease on CT imaging. Five (50%) of these 10 patients were found to have residual tumor cells on pathologic analysis. Tumor cells were contained only to those levels found positive on CT imaging; they were present in 7 (50%) of the 14 positive levels.</p>
<p><b>Conclusions&nbsp;</b> Neck levels with residual disease on post-CRT CT imaging warrant removal. However, neck levels without evidence of disease on post-CRT CT imaging are unlikely to harbor cancer, which lends further support to the concept of basing neck dissection on post-CRT staging and performance of limited neck dissections for patients with limited residual disease.</p>
]]></description>
<dc:creator><![CDATA[Langerman, A., Plein, C., Vokes, E. E., Salama, J. K., Haraf, D. J., Blair, E. A., Stenson, K. M.]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:subject><![CDATA[Oncology, Head & Neck Cancer, Otolaryngology/ Head & Neck Surgery, Neoplasms of Head & Neck, Radiology of Head & Neck, Radiation Therapy, Drug Therapy, Drug Therapy, Other]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.154</dc:identifier>
<dc:title><![CDATA[Neck Response to Chemoradiotherapy: Complete Radiographic Response Correlates With Pathologic Complete Response in Locoregionally Advanced Head and Neck Cancer [Original Article]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1136</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1133</prism:startingPage>
<prism:section>Original Article</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1136?rss=1">
<title><![CDATA[Error in Text in: Comparison of Clinical and Pathological Staging in Head and Neck Squamous Cell Carcinoma: Results From Intergroup Study ECOG 4393/RTOG 9614 [Correction]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1136?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:subject><![CDATA[Oncology, Head & Neck Cancer, Skin Cancer, Otolaryngology/ Head & Neck Surgery, Neoplasms of Head & Neck, Prognosis/ Outcomes]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.172</dc:identifier>
<dc:title><![CDATA[Error in Text in: Comparison of Clinical and Pathological Staging in Head and Neck Squamous Cell Carcinoma: Results From Intergroup Study ECOG 4393/RTOG 9614 [Correction]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1136</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1136</prism:startingPage>
<prism:section>Correction</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1137?rss=1">
<title><![CDATA[Immune Response During Therapy With Cisplatin or Radiation for Human Papillomavirus-Related Head and Neck Cancer [Original Article]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1137?rss=1</link>
<description><![CDATA[
<p><b>Background&nbsp;</b> Human papillomavirus (HPV) is the most identifiable cause of head and neck squamous cell cancer (HNSCC). Compared with HPV-negative HNSCC, HPV-positive HNSCC presents at an advanced stage but with significantly better survival. We created a syngeneic mouse model of HPV-positive and HPV-negative HNSCC by transforming mouse primary tonsil epithelial cells with either HPV oncogenes or a nonantigenic RNA interference strategy that affects similar oncogenic pathways.</p>
<p><b>Objectives&nbsp;</b> To examine the effect of radiation therapy on HPV-positive and HPV-negative tumors in immune-competent and immune-incompetent mice and to examine responses in human cancer cell lines.</p>
<p><b>Design&nbsp;</b> Prospective in vivo murine model.</p>
<p><b>Main Outcome Measures&nbsp;</b> Survival and tumor growth.</p>
<p><b>Results&nbsp;</b> For human and murine transformed cell lines, HPV-positive cells were more resistant to radiation and cisplatin therapy compared with HPV-negative cells. In vivo, HPV-positive tumors were more sensitive to radiation, with complete clearance at 20 Gy, compared with their HPV-negative counterparts, which showed persistent growth. Cisplatin in vivo cleared HPV-positive tumors but not HPV-negative tumors. However, neither radiation or cisplatin therapy cured immune-incompetent mice. Adoptive transfer of wild-type immune cells into immune-incompetent mice restored HPV-positive tumor clearance with cisplatin therapy.</p>
<p><b>Conclusions&nbsp;</b> The HPV-positive tumors are not more curable based on increased epithelial sensitivity to cisplatin or radiation therapy. Instead, radiation and cisplatin induce an immune response to this antigenic cancer. The implications of these results may lead to novel therapies that enhance tumor eradication for HPV-positive cancers.</p>
]]></description>
<dc:creator><![CDATA[Spanos, W. C., Nowicki, P., Lee, D. W., Hoover, A., Hostager, B., Gupta, A., Anderson, M. E., Lee, J. H.]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:subject><![CDATA[Oncology, Head & Neck Cancer, Oncology, Other, Otolaryngology/ Head & Neck Surgery, Neoplasms of Head & Neck, Radiation Therapy, Drug Therapy, Drug Therapy, Other, Immunology, Immunology, Other]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.159</dc:identifier>
<dc:title><![CDATA[Immune Response During Therapy With Cisplatin or Radiation for Human Papillomavirus-Related Head and Neck Cancer [Original Article]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1146</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1137</prism:startingPage>
<prism:section>Original Article</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1147?rss=1">
<title><![CDATA[A 25-Year Analysis of Veterans Treated for Tonsillar Squamous Cell Carcinoma [Original Article]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1147?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To determine the recurrence and survival outcome based on treatment date, type of treatment, stage of disease, and comorbidity and the recurrence and survival differences based on smoking status as a surrogate for human papillomavirus status in veterans treated for tonsillar squamous cell carcinoma (SCC).</p>
<p><b>Design&nbsp;</b> Outcome cohort study.</p>
<p><b>Setting&nbsp;</b> Tertiary care Department of Veterans Affairs hospital.</p>
<p><b>Patients&nbsp;</b> A consecutive sample from 1981 through 2006 of 683 patients treated for oropharyngeal SCC was screened, and 141 patients with tonsillar SCC without distant metastatic spread and a minimum of 2 years of follow-up were included.</p>
<p><b>Main Outcome Measures&nbsp;</b> Disease-free survival (DFS), disease-specific survival (DSS), and overall survival (OS).</p>
<p><b>Results&nbsp;</b> Disease-free survival was significantly better in cohort II (treated during or after 1997) compared with cohort I (treated before 1997) (2- and 5-year DFS, 82% vs 64% and 67% vs 48%; <I>P</I>&nbsp;=&nbsp;.02). Disease-specific survival was better in the surgical vs nonsurgical group (2- and 5-year DSS, 77% vs 46% and 67% vs 30%; <I>P</I>&nbsp;&lt;&nbsp;.001), as was the OS (2- and 5-year OS, 66% vs 41% and 45% vs 23%; <I>P</I>&nbsp;=&nbsp;.005). In subjects with early-stage disease, OS and DSS were not different regardless of treatment type. In subjects with late-stage disease treated most recently (time cohort II), there was significantly better DSS in those receiving surgical vs nonsurgical treatment (2-year DSS, 70% vs 43%; <I>P</I>&nbsp;=&nbsp;.045). Nonsmokers had better OS (94 months vs 41 months; <I>P</I>&nbsp;=&nbsp;.001) and lower incidence of recurrence (8% vs 44%; <I>P</I>&nbsp;=&nbsp;.02).</p>
<p><b>Conclusion&nbsp;</b> In veterans treated for tonsillar SCC, we advocate the consideration of a treatment plan that includes surgery for patients presenting with advanced-stage SCC of the tonsil, even in patients with notable comorbidities.</p>
]]></description>
<dc:creator><![CDATA[Jaber, J. J., Moreira, J., Canar, W. J., Bier-Laning, C. M.]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:subject><![CDATA[Oncology, Head & Neck Cancer, Oncology, Other, Otolaryngology/ Head & Neck Surgery, Neoplasms of Head & Neck, Public Health, Tobacco, Radiation Therapy, Surgery, Surgical Interventions, Surgical Oncology, Prognosis/ Outcomes]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.164</dc:identifier>
<dc:title><![CDATA[A 25-Year Analysis of Veterans Treated for Tonsillar Squamous Cell Carcinoma [Original Article]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1153</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1147</prism:startingPage>
<prism:section>Original Article</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1154?rss=1">
<title><![CDATA[Factors That Predict Postoperative Pulmonary Complications After Supracricoid Partial Laryngectomy [Original Article]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1154?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To determine the risk factors related to postoperative pulmonary complications in patients who undergo supracricoid partial laryngectomy.</p>
<p><b>Design&nbsp;</b> Retrospective analysis of medical records.</p>
<p><b>Setting&nbsp;</b> Tertiary care referral center.</p>
<p><b>Patients&nbsp;</b> One hundred eleven patients who underwent supracricoid partial laryngectomy from January 1, 1993, through December 31, 2008.</p>
<p><b>Main Outcome Measures&nbsp;</b> Relationship between postoperative pulmonary complications and perioperative risk factors, such as age, sex, chronic lung disease, smoking status, tumor site, tumor stage, preoperative irradiation, extent of surgery, reconstruction method, and pulmonary function tests.</p>
<p><b>Results&nbsp;</b> Thirty-six patients (32.4%) developed postoperative pulmonary complications. Significant correlations were found among age (<I>P</I>&nbsp;=&nbsp;.002), chronic lung disease (<I>P</I>&nbsp;=&nbsp;.005), smoking status (<I>P</I>&nbsp;=&nbsp;.02), and postoperative pulmonary complications. Cricohyoidopexy (<I>P</I>&nbsp;=&nbsp;.008) and ipsilateral arytenoidectomy (<I>P</I>&nbsp;=&nbsp;.03) were associated with postoperative pulmonary complications. The multivariate analysis showed a significant association of the postoperative pulmonary complications with age (odds ratio [OR],&nbsp;3.8; 95% confidence interval [CI], 1.2-11.7 in patients 60 to 69 years old; and OR,&nbsp;7.1; 95% CI, 1.3-37.6 in patients 70 to 79 years old) and cricohyoidopexy (OR, 4.4; 95% CI, 1.1-18.1).</p>
<p><b>Conclusion&nbsp;</b> Patients 60 years or older and patients with cricohyoidopexy are at high risk of having postoperative pulmonary complications after supracricoid partial laryngectomy.</p>
]]></description>
<dc:creator><![CDATA[Joo, Y.-H., Sun, D.-I., Cho, J.-H., Cho, K.-J., Kim, M.-S.]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:subject><![CDATA[Aging/ Geriatrics, Bacterial Infections, Oncology, Head & Neck Cancer, Otolaryngology/ Head & Neck Surgery, Neoplasms of Head & Neck, Pulmonary Diseases, Pneumonia, Pulmonary Diseases, Other, Surgery, Surgical Interventions, Surgical Oncology, Infectious Diseases]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.149</dc:identifier>
<dc:title><![CDATA[Factors That Predict Postoperative Pulmonary Complications After Supracricoid Partial Laryngectomy [Original Article]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1157</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1154</prism:startingPage>
<prism:section>Original Article</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1158?rss=1">
<title><![CDATA[Postoperative Reirradiation for Mucosal Head and Neck Squamous Cell Carcinomas [Original Article]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1158?rss=1</link>
<description><![CDATA[
<p><b>Objectives&nbsp;</b> To compare toxic effects and functional outcomes of reirradiation with and without salvage surgery for nonnasopharyngeal mucosal head and neck squamous cell carcinoma.</p>
<p><b>Design&nbsp;</b> Retrospective review.</p>
<p><b>Setting&nbsp;</b> Academic tertiary referral hospital.</p>
<p><b>Patients&nbsp;</b> Between December 1992 and March 2007, a total of 87 patients underwent reirradiation (64 for cure and 23 for palliation).</p>
<p><b>Intervention&nbsp;</b> Patients underwent reirradiation with (n&nbsp;=&nbsp;38) or without salvage surgery (n&nbsp;=&nbsp;49). After January 2000 there was increased use of concurrent platinum-based chemotherapy (80% vs 5%) and intensity-modulated radiation therapy (82% vs 0%).</p>
<p><b>Main Outcome Measures&nbsp;</b> Early and late toxic effects of treatment by Radiation Therapy Oncology Group criteria, tracheostomy retention, gastrostomy tube dependence, and survival.</p>
<p><b>Results&nbsp;</b> The median follow-up among patients alive at last contact was 5.0 years. Compared with reirradiation without surgery, postoperative reirradiation was associated with increased early grade 3 to grade 5 toxic effects (50% [19 of 38] vs 29% [14 of 49], <I>P</I>&nbsp;=&nbsp;.04) and with longer median survival (17.3 vs 8.9 months, <I>P</I>&nbsp;&lt;&nbsp;.001). Free-flap reconstruction decreased early toxic effects in the surgical cohort by 16% (from 60% [9 of 15] to 43% [10 of 23], <I>P</I>&nbsp;=&nbsp;.32). Gastrostomy tube dependence (<I>P</I>&nbsp;=&nbsp;.05) and tracheostomy retention (<I>P</I>&nbsp;=&nbsp;.04) have increased since 2000. The median survival for curative patients was 12.5 months. The estimated 2-year survival was 25%, and the estimated 5-year survival was 8%.</p>
<p><b>Conclusions&nbsp;</b> Reirradiation represents the only chance for cure in patients with unresectable disease. After surgery, reirradiation is performed in patients at high risk of locoregional recurrence and may increase acute toxic effects. However, free-flap reconstruction may reduce toxic effects. Functional outcomes have declined since 2000 likely because of the addition of concurrent platinum-based chemotherapy. Future research may define the subpopulation of postoperative patients for whom survival benefits most outweigh reirradiation toxic effects.</p>
]]></description>
<dc:creator><![CDATA[Iseli, T. A., Iseli, C. E., Rosenthal, E. L., Caudell, J. J., Spencer, S. A., Magnuson, J. S., Smith, A. N., Carroll, W. R.]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:subject><![CDATA[Oncology, Head & Neck Cancer, Oncology, Other, Otolaryngology/ Head & Neck Surgery, Neoplasms of Head & Neck, Radiation Therapy]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.161</dc:identifier>
<dc:title><![CDATA[Postoperative Reirradiation for Mucosal Head and Neck Squamous Cell Carcinomas [Original Article]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1164</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1158</prism:startingPage>
<prism:section>Original Article</prism:section>
</item>

<item rdf:about="http://archotol.ama-assn.org/cgi/content/short/135/11/1165?rss=1">
<title><![CDATA[Complications That Affect Postlaryngectomy Voice Restoration: Primary Surgery vs Salvage Surgery [Original Article]]]></title>
<link>http://archotol.ama-assn.org/cgi/content/short/135/11/1165?rss=1</link>
<description><![CDATA[
<p><b>Objective&nbsp;</b> To assess the effect of primary treatment on tracheoesophageal voice prosthesis (TEP) complications.</p>
<p><b>Design&nbsp;</b> Retrospective cohort study.</p>
<p><b>Setting&nbsp;</b> The Johns Hopkins Medical Institutions, Baltimore, Maryland.</p>
<p><b>Patients&nbsp;</b> Patients who underwent total laryngectomy and TEP between January 1, 1998, and December 31, 2008, were divided into 3 subgroups according to primary treatment: surgery (n&nbsp;=&nbsp;81), radiotherapy (n&nbsp;=&nbsp;61), and chemoradiotherapy (n&nbsp;=&nbsp;32).</p>
<p><b>Main Outcome Measures&nbsp;</b> Number of weeks before leakage through the TEP, occurrence of leakage around the TEP, TEP dislodgement, and size changes 6 months or longer after laryngectomy.</p>
<p><b>Results&nbsp;</b> A total of 174 patients met the study criteria. Of the 81 patients who underwent primary surgery, 81% (n&nbsp;=&nbsp;66) underwent adjuvant therapy with postoperative radiotherapy or chemoradiotherapy. The incidence of leakage around the prosthesis, prosthesis dislodgement, and size changes 6 months or longer after laryngectomy were significantly higher for patients who required salvage total laryngectomy after chemoradiotherapy or radiotherapy (<I>P</I>&nbsp;&lt;&nbsp;.05). In addition, significantly more patients who underwent salvage total laryngectomy required extended laryngectomy or free tissue reconstruction.</p>
<p><b>Conclusions&nbsp;</b> Voice prosthesis complications are more frequently encountered in those who require salvage laryngectomy. Understanding the potential for such complications reinforces the need for close communication and follow-up with these patients by the speech language pathologist.</p>
]]></description>
<dc:creator><![CDATA[Starmer, H. M., Ishman, S. L., Flint, P. W., Bhatti, N. I., Richmon, J., Koch, W., Webster, K., Tufano, R., Gourin, C. G.]]></dc:creator>
<dc:date>Mon, 16 Nov 2009 12:51:31 PST</dc:date>
<dc:subject><![CDATA[Otolaryngology/ Head & Neck Surgery, Laryngology/ Speech/ Language Pathology, Neoplasms of Head & Neck, Voice Disorders]]></dc:subject>
<dc:identifier>info:doi/10.1001/archoto.2009.168</dc:identifier>
<dc:title><![CDATA[Complications That Affect Postlaryngectomy Voice Restoration: Primary Surgery vs Salvage Surgery [Original Article]]]></dc:title>
<dc:publisher>American Medical Association</dc:publisher>
<prism:number>11</prism:number>
<prism:volume>135</prism:volume>
<prism:endingPage>1169</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1165</prism:startingPage>
<prism:section>Original Article</prism:section>
</item>

</rdf:RDF>